Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
The Candel Therapeutics, Inc. (CADL) news page on Stock Titan aggregates company-issued updates, press releases, and related coverage focused on its multimodal viral immunotherapy programs in oncology. Candel describes itself as a clinical-stage biopharmaceutical company developing off-the-shelf biological immunotherapies based on genetically modified adenovirus and herpes simplex virus (HSV) constructs, with lead candidates CAN-2409 and CAN-3110 in solid tumors.
Visitors to this page can follow announcements about clinical trial progress, including pivotal and phase 2 studies of CAN-2409 in intermediate-to-high-risk localized prostate cancer, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma (PDAC), as well as phase 1b data for CAN-3110 in recurrent high-grade glioma. Candel’s releases also highlight regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug Designation granted by the U.S. Food and Drug Administration for specific indications.
News items frequently cover scientific presentations at major conferences, including ASTRO, ASCO, and the Society for Immunotherapy of Cancer (SITC), where Candel discusses subgroup analyses, biomarker findings, and multi-omics data related to its viral immunotherapy approach. Additional updates describe financing transactions, such as equity offerings and a term loan facility, as well as corporate developments like research advisory board appointments and investor conference participation.
By reviewing the CADL news feed, investors and researchers can see how Candel communicates the evolution of its CAN-2409 and CAN-3110 programs, the role of the enLIGHTEN™ Discovery Platform, and key milestones disclosed in its own press releases and referenced in SEC filings. Bookmark this page to access a centralized view of Candel’s publicly released information on its oncology-focused pipeline and corporate activities.
Candel Therapeutics (Nasdaq: CADL) announced inducement stock option grants on March 31, 2026 to five new employees totaling 70,000 options at a $4.90 exercise price.
The options were granted under the company’s 2025 Inducement Plan, adopted December 24, 2025, and vest 25% after one year, then monthly over 36 months, subject to continued service.
Candel Therapeutics (Nasdaq: CADL) reported extended follow-up from a Phase 2a study of aglatimagene besadenovec (CAN-2409) plus valacyclovir with continued ICI in advanced NSCLC. Among 46 per-protocol patients, 50% were alive at 24 months and median overall survival was 25.4 months.
Tumor biopsies showed increased pro-inflammatory gene expression and expanded T-cell receptor diversity, findings the company links to durable anti-tumor immunity. A pivotal Phase 3 trial in non-squamous NSCLC is planned to start in Q2 2026; FDA Fast Track designation is already in place.
Candel Therapeutics (Nasdaq: CADL) reported Q4 and full‑year 2025 results and corporate updates on March 12, 2026, highlighting clinical and financing milestones.
Key items: planned pivotal phase 3 NSCLC trial start in Q2 2026, a planned BLA submission for aglatimagene in Q4 2026, IND clearance for linoserpaturev (CAN-3110), a $130M term loan facility ( $50M drawn) and cash of $119.7M as of Dec 31, 2025 plus follow-on proceeds supporting runway into Q1 2028.
Candel Therapeutics (NASDAQ: CADL) will present updated, extended-follow-up data from its randomized Phase 3 trial of aglatimagene besadenovec (CAN-2409) in intermediate- to high-risk localized prostate cancer at the AUA 2026 Annual Meeting in Washington, D.C., on May 15, 2026.
The oral plenary will report accumulating benefit for patients treated with CAN-2409 plus prodrug combined with standard external beam radiation; full abstracts and presentation details will be released at the event and posted by the company afterward.
Candel Therapeutics (Nasdaq: CADL) announced that on February 28, 2026 its Compensation Committee granted inducement stock options to one new employee to purchase 20,000 shares at an exercise price of $5.25 per share under the company's 2025 Inducement Plan.
Vesting: 25% after one year of service, then the remaining 75% vesting in 36 equal monthly installments, all subject to continued employment. The Plan was adopted on December 24, 2025 and the awards comply with Nasdaq Listing Rule 5635(c)(4).
Candel Therapeutics (Nasdaq: CADL) announced that Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO, will present at TD Cowen’s 46th Annual Health Care Conference in Boston on Tuesday, March 3, 2026, 11:50 AM - 12:20 PM ET.
A live webcast will be available via the company’s Investors > Events and Presentations page at www.candeltx.com, and a replay will be archived for up to 90 days after the session.
Candel Therapeutics (Nasdaq: CADL) priced an underwritten public offering of 18,348,624 common shares at $5.45 per share, expected to raise approximately $100 million gross. The offering is expected to close on or about Feb 23, 2026.
The company granted a 30-day underwriter option for up to 2,752,293 additional shares. Net proceeds are intended to fund launch readiness and commercial activities for CAN-2409 (aglatimagene) in localized prostate cancer, support the phase 3 NSCLC program, and for general corporate purposes.
Candel Therapeutics (Nasdaq: CADL) announced a proposed underwritten public offering of $100 million of common stock, with a 30-day underwriter option for an additional $15 million. The company intends to use net proceeds to support launch readiness and commercialization of CAN-2409 (aglatimagene) in early localized prostate cancer, fund ongoing phase 3 development in non-small cell lung cancer (NSCLC), and for general corporate purposes.
The offering is subject to market conditions and will be made under a shelf registration declared effective by the SEC on August 22, 2025. Citigroup, Cantor, and Stifel are joint bookrunners.
Candel Therapeutics (Nasdaq: CADL) announced a $100 million royalty funding agreement with RTW to support a potential U.S. launch of aglatimagene besadenovec (CAN-2409) for intermediate- to high-risk localized prostate cancer, contingent on FDA approval and customary conditions.
Funds will be available upon approval; RTW will receive a tiered single-digit percentage of U.S. annual net sales, subject to a cap. Candel expects to submit a BLA in Q4 of this year and cites pivotal phase 3 data as the rationale for commercial potential.
Candel Therapeutics (Nasdaq: CADL) announced that Dr. Francesca Barone, Chief Scientific Officer, will present and take part in panels at the 7th Annual Glioblastoma Drug Development Summit in Boston, Feb 17–19, 2026. Presentations will cover the HSV-based platform and linoserpaturev (CAN-3110) program in recurrent high-grade glioma, focusing on biomarker-driven clinical development, imaging integration, and biomarker-based enrollment strategies to inform patient stratification and response assessment.